Target Price | $49.47 |
Price | $35.20 |
Potential |
40.54%
register free of charge
|
Number of Estimates | 12 |
12 Analysts have issued a price target Harmony Biosciences Holdings 2026 .
The average Harmony Biosciences Holdings target price is $49.47.
This is
40.54%
register free of charge
$73.50
108.81%
register free of charge
$31.31
11.05%
register free of charge
|
|
A rating was issued by 15 analysts: 13 Analysts recommend Harmony Biosciences Holdings to buy, 1 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Harmony Biosciences Holdings stock has an average upside potential 2026 of
40.54%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 714.73 | 860.04 |
22.80% | 20.33% | |
EBITDA Margin | 30.08% | 36.07% |
18.86% | 19.91% | |
Net Margin | 20.29% | 22.33% |
8.47% | 10.07% |
12 Analysts have issued a sales forecast Harmony Biosciences Holdings 2025 . The average Harmony Biosciences Holdings sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Harmony Biosciences Holdings EBITDA forecast 2025. The average Harmony Biosciences Holdings EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Harmony Biosciences Holdings Analysts have issued a net profit forecast 2025. The average Harmony Biosciences Holdings net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 2.51 | 3.37 |
16.74% | 34.26% | |
P/E | 10.45 | |
EV/Sales | 1.97 |
11 Analysts have issued a Harmony Biosciences Holdings forecast for earnings per share. The average Harmony Biosciences Holdings EPS is
This results in the following potential growth metrics and future valuations:
Harmony Biosciences Holdings...
Analyst | Rating | Action | Date |
---|---|---|---|
Deutsche Bank |
Locked
➜
Locked
|
Locked | Jul 10 2025 |
Mizuho |
Locked
➜
Locked
|
Locked | May 15 2025 |
Needham |
Locked
➜
Locked
|
Locked | May 07 2025 |
Needham |
Locked
➜
Locked
|
Locked | May 06 2025 |
UBS |
Locked
➜
Locked
|
Locked | Apr 28 2025 |
Needham |
Locked
➜
Locked
|
Locked | Apr 10 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
Analyst Rating | Date |
---|---|
Locked
Deutsche Bank:
Locked
➜
Locked
|
Jul 10 2025 |
Locked
Mizuho:
Locked
➜
Locked
|
May 15 2025 |
Locked
Needham:
Locked
➜
Locked
|
May 07 2025 |
Locked
Needham:
Locked
➜
Locked
|
May 06 2025 |
Locked
UBS:
Locked
➜
Locked
|
Apr 28 2025 |
Locked
Needham:
Locked
➜
Locked
|
Apr 10 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 08 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.